The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Loss from discontinued operations, net of tax | 0 | - | - |
| Net loss from continuing operations | -2,037,819 | - | - |
| Net loss | -6,369,407 | - | - |
| Change in fair value of derivative liabilities | 0 | 0 | - |
| Gain on voluntary conversion of convertible debt | 0 | - | - |
| Loss on monthly redemptions of convertible debt into common stock | 0 | 0 | - |
| Accretion of discount on convertible debt | 0 | 0 | - |
| Gain on change in fair value of derivative liabilities | 0 | - | - |
| Fair value of warrant modification for professional services | 0 | 0 | - |
| Net loss from continuing operations | -2,037,819 | -4,331,588 | - |
| Stock-based compensation | 0 | 0 | 269 |
| Change in fair value of warrant liabilities | 148,347 | -15,974 | -39,225 |
| Legal expenses deducted from issuance of converftible debt | 0 | 20,000 | - |
| Amortization of accrued penalty on notes payable | - | - | 73,615 |
| Issuance of common stock to consultant | 325,635 | - | - |
| Accrued interest on short-term note receivable | 177,611 | 140,433 | 110,871 |
| Gain on voluntary conversion of convertible debt | - | 0 | - |
| Amortization of penalty on promissory note | 455,940 | 179,667 | - |
| Loss on issuance of convertible debt | 0 | -91,943 | - |
| Loss on change in fair value of convertible debt | -197,667 | 37,874 | - |
| Prepaid expenses and other assets | 26,515 | -269,189 | -913,454 |
| Accounts payable | -122,387 | -126,124 | -37,330 |
| Accrued expenses and other current liabilities | -337,737 | 149,529 | 59,861 |
| Provision for credit losses of short-term note receivable | -567,000 | 271,000 | 197,000 |
| Net cash used in operating activities | -2,141,478 | -1,098,111 | -1,589,396 |
| Net cash provided by investing activities - discontinued operations | 0 | 0 | - |
| Issuance of short-term note receivable | 291,000 | 1,213,500 | 305,000 |
| Net cash used in investing activities | -291,000 | -1,213,500 | -305,000 |
| Net cash provided by financing activities - discontinued operations | 0 | 0 | 0 |
| Proceeds from issuance of common shares and prefunded warrants in public offering | 0 | - | - |
| Proceeds from warrant exercises | 0 | 0 | - |
| Proceeds from the issuance of convertible debt | 0 | 200,000 | - |
| Net proceeds from issuance of common and preferred shares in private placement | 41,911,544 | - | - |
| Repayment of convertible debt | 0 | 132,000 | - |
| Proceeds from issuance of short term debt | - | - | 750,000 |
| Repayment of promissory notes | 1,033,500 | - | - |
| Proceeds from the issuance of convertible notes payable | - | - | 0 |
| Proceeds from issuance of promissory notes | 0 | 3,295,000 | - |
| Net cash provided by financing activities - continuing operations | 40,878,044 | 2,613,000 | 750,000 |
| Net cash provided by financing activities | 40,878,044 | 2,613,000 | 750,000 |
| Net change in cash and cash equivalents | 38,445,565 | 301,389 | -1,144,396 |
| Cash and cash equivalents at beginning of period | 1,174,608 | - | - |
| Cash and cash equivalents at end of period | 38,777,166 | - | - |
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)